F12.50 ICD-10-CA code: Mental and behavioural disorders due to use of cannabinoids, psychotic disorder
F12.50 is the ICD-10-CA code for “Mental and behavioural disorders due to use of cannabinoids, psychotic disorder” in CIHI’s FY 2026–2027 release, in effect from Apr 1, 2026.
Official description
F12.50Mental and behavioural disorders due to use of cannabinoids, psychotic disorder
Short description: Ment/beh dis dt cannab psychtc d/o
ICD-10-CA · Canada · Also written F1250
Index terms
Entries in CIHI’s alphabetical index that lead to F12.50. Searching the index by the condition the note names is how coders reach this code.
- Disorder (of), psychotic (due to), cannabinoids (from cannabis plant) (immediate)
- Disorder (of), psychotic (due to), cannabis (and derivatives) (indica) (marijuana) (plant) (sativa) (immediate)
Notes for F12.50
As CIHI prints them, with any note F12.50 takes from the headings above it.
Includes
- Disorders of psychological developmentFrom Chapter 5: Mental and behavioural disorders (F00-F99)
Excludes
Conditions classified elsewhere.
- Alcohol- or other psychoactive substance-induced residual and late-onset psychotic disorder (F10-F19 with common fourth character .7)From F12.5 Mental and behavioural disorders due to use of cannabinoids, psychotic disorder
- Abuse of non-dependence-producing substances (F55)From F10-F19 Mental and behavioural disorders due to psychoactive substance use
- Symptoms, signs and abnormal clinical laboratory findings, not elsewhere classified (R00-R99)From Chapter 5: Mental and behavioural disorders (F00-F99)
Note
- A cluster of psychotic phenomena that occur during or following psychoactive substance use but that are not explained on the basis of acute intoxication alone and do not form part of a withdrawal state. The disorder is characterized by hallucinations (typically auditory, but often in more than one sensory modality), perceptual distortions, delusions (often of a paranoid or persecutory nature), psychomotor disturbances (excitement or stupor), and an abnormal affect, which may range from intense fear to ecstasy. The sensorium is usually clear but some degree of clouding of consciousness, though not severe confusion, may be present.From F12.5 Mental and behavioural disorders due to use of cannabinoids, psychotic disorder
- This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth-character codes are applicable to all substances.Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9).Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used.From F10-F19 Mental and behavioural disorders due to psychoactive substance use
Where F12.50 sits
- 1ChapterChapter 5: Mental and behavioural disorders (F00-F99)
- 2Block F10-F19Mental and behavioural disorders due to psychoactive substance use
- 3Category F12Mental and behavioural disorders due to use of cannabinoids
- 4Subcategory F12.5Mental and behavioural disorders due to use of cannabinoids, psychotic disorder
- 5Valid code F12.50Mental and behavioural disorders due to use of cannabinoids, psychotic disorder
Source and release
- Data release
- ICD-10-CA · FY 2026–2027
- Effective date
- Apr 1, 2026
- Publisher
- CIHI
This page is built from the ICD-10-CA catalog that Vero Codes reads when it suggests codes: Canadian Institute for Health Information’s FY 2026–2027 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does ICD-10-CA code F12.50 mean?
F12.50 is the ICD-10-CA code for “Mental and behavioural disorders due to use of cannabinoids, psychotic disorder” in CIHI’s ICD-10-CA FY 2026–2027 release.
Where is F12.50 in ICD-10-CA?
F12.50 sits under F12.5 Mental and behavioural disorders due to use of cannabinoids, psychotic disorder, within F12 Mental and behavioural disorders due to use of cannabinoids, within F10-F19 Mental and behavioural disorders due to psychoactive substance use, within Chapter 5: Mental and behavioural disorders (F00-F99).
What coding notes apply to F12.50?
ICD-10-CA lists Note, Excludes, Includes notes for F12.50, including those from the headings it sits under. They are listed on this page with where each one comes from.
Which ICD-10-CA release does this page use?
It uses CIHI’s FY 2026–2027 release, in effect from Apr 1, 2026 to Mar 31, 2027. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.